A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 841 participants.

Also called NCT01128894

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 841 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01128894
Other papers using this trial's data
  • Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study The lancet. Diabetes & endocrinology, 2014-04 DOI, PubMed 24703047

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Israel, Peru, Philippines, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01128894. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2014-05-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Condition
Diabetes Mellitus, Type 2
Intervention (Biological)
albiglutide
Intervention (Drug)
liraglutide
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01128894
Content hash
f0cdf32f3adceecbf5986281cf0202cd9aa70044820c81ef03d7a12ac6233dbc